Literature DB >> 24002055

Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case-control study.

Vidya Navaratnam1, Andrew W Fogarty, Tricia McKeever, Norma Thompson, Gisli Jenkins, Simon R Johnson, Gerard Dolan, Maruti Kumaran, Kate Pointon, Richard B Hubbard.   

Abstract

BACKGROUND: Laboratory studies suggest that the clotting cascade is activated in fibrotic lungs. Since humans vary in their tendency to clot due to a variety of inherited or acquired defects, we investigated whether a prothrombotic state increases the chance of developing idiopathic pulmonary fibrosis (IPF) and/or worsens the prognosis of IPF.
METHODS: We recruited 211 incident cases of IPF and 256 age- and sex-matched general population controls and collected data on medical history, medication, smoking habit, blood samples as well as lung function and high-resolution CT scans done as part of routine clinical care. A prothrombotic state was defined as the presence of at least one inherited or acquired clotting defect or marker of fibrinolytic dysfunction. We used logistic regression to quantify the association between a prothrombotic state and IPF adjusted for age, sex, smoking habit and highly sensitive C reactive protein. Cox regression was used to determine the influence of a prothrombotic state on survival.
RESULTS: Cases were more than four times more likely than controls to have a prothrombotic state (OR 4.78, 95% CI 2.93 to 7.80; p<0.0001). Cases with a prothrombotic state were also likely to have more severe disease (forced vital capacity <70% predicted) at presentation (OR 10.79, 95% CI 2.43 to 47.91) and had a threefold increased risk of death (HR 3.26, 95% CI 1.09 to 9.75).
CONCLUSIONS: People with IPF are more likely to have a prothrombotic state than general population controls and the presence of a prothrombotic state has an adverse impact on survival.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis; Interstitial Fibrosis

Mesh:

Substances:

Year:  2013        PMID: 24002055     DOI: 10.1136/thoraxjnl-2013-203740

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  27 in total

Review 1.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 2.  Risk of venous thromboembolism in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.

Authors:  Boonphiphop Boonpheng; Patompong Ungprasert
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

Review 3.  Mesenchymal Stem/Stromal Cells in Progressive Fibrogenic Involvement and Anti-Fibrosis Therapeutic Properties.

Authors:  Chenghai Li; Bin Wang
Journal:  Front Cell Dev Biol       Date:  2022-06-01

Review 4.  New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.

Authors:  Neil Ahluwalia; Barry S Shea; Andrew M Tager
Journal:  Am J Respir Crit Care Med       Date:  2014-10-15       Impact factor: 21.405

Review 5.  The Prognosis of Arthrofibroses: Prevalence, Clinical Shortcomings, and Future Prospects.

Authors:  William A Blessing; Amanda K Williamson; Jack R Kirsch; Mark W Grinstaff
Journal:  Trends Pharmacol Sci       Date:  2021-03-29       Impact factor: 14.819

6.  Associations of D-Dimer with Computed Tomographic Lung Abnormalities, Serum Biomarkers of Lung Injury, and Forced Vital Capacity: MESA Lung Study.

Authors:  John S Kim; Michaela R Anderson; Elana J Bernstein; Elizabeth C Oelsner; Ganesh Raghu; Imre Noth; Michael Y Tsai; Mary Salvatore; John H M Austin; Eric A Hoffman; R Graham Barr; Anna J Podolanczuk
Journal:  Ann Am Thorac Soc       Date:  2021-11

Review 7.  Venous Thromboembolic Disease in Chronic Inflammatory Lung Diseases: Knowns and Unknowns.

Authors:  George Keramidas; Konstantinos I Gourgoulianis; Ourania S Kotsiou
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241

Review 8.  Pathogenesis of idiopathic pulmonary fibrosis: review of recent findings.

Authors:  Elisabetta Renzoni; Veeraraghavan Srihari; Piersante Sestini
Journal:  F1000Prime Rep       Date:  2014-08-01

9.  High endogenous activated protein C levels attenuates bleomycin-induced pulmonary fibrosis.

Authors:  Cong Lin; Jan von der Thüsen; Berend Isermann; Hartmut Weiler; Tom van der Poll; Keren Borensztajn; Chris A Spek
Journal:  J Cell Mol Med       Date:  2016-06-14       Impact factor: 5.310

10.  Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.

Authors:  Toby M Maher; Maria Molina-Molina; Anne-Marie Russell; Francesco Bonella; Stéphane Jouneau; Elena Ripamonti; Judit Axmann; Carlo Vancheri
Journal:  BMC Pulm Med       Date:  2017-09-15       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.